18 Oct 2026 · Everyday · Structure
In 2019 the same cap on cancer medicines came with the line "up to 87%" cheaper. In its first list of 426 brands, only 38 fell 75% or more. The brand in the middle, with half falling more and half less, fell by a quarter to a half.
The cap is on the trade margin, the share of the printed price (MRP) kept along the way by wholesalers, chemists and hospitals. On 17 Oct 2026 the government limited it to 30% of the MRP for 137 cancer drugs from 9 Nov, and said prices may fall "up to 70%" (PIB). The 2019 cap was the same 30%, on 42 drugs.
In that first 2019 list (PIB, 8 Mar 2019), 107 brands fell by less than a quarter and 36 did not fall at all.
The catch: this year's list has more than three times as many drugs, including immunotherapy drugs (medicines that help the body's own defences fight cancer), so the spread may not repeat.
"Up to" is the biggest cut, not the usual one: how much a medicine falls depends on how big its margin was.
Research, not advice. Do your own work.
